Assessment of cardiac sarcoidosis by using PET tracer 18F-FMISO that accumulates in hypoxic tissues

Assessment of cardiac sarcoidosis by using PET tracer 18F-FMISO that accumulates in hypoxic tissues - Assessment of cardiac sarcoidosis by using 18F-FMISO

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031988

Enrollment

Registered

2018-03-30

Start date

2018-03-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac sarcoidosis

Interventions

We intervene in patients for suspected or diagnosed cardiac sarcoidosis. FDG PET and FMISO PET are performed and we investigate the results. FMISO PET is performed before and during steroid therapy.FD

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients for suspected or diagnosed cardiac sarcoidosis. Patients who met the diagnostic criteria of cardiac sarcoidosis.

Exclusion criteria

Exclusion criteria: Steroid therapy was initiated prior to the first scan.

Design outcomes

Primary

Measure	Time frame
Assessment of FMISO uptake to cardiac sarcoidosis leisons.	—

Secondary

Measure	Time frame
Sensitivity and specificity for diagnose cardiac sarcoidosis. A correlation coefficient between FMISO uptake and FDG uptake.	—

Countries

Japan

Contacts

Public ContactSho Furuya

Hokkaido University Department of nuclear medicine

s42090092o@gmail.com011-706-5152

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026